EnglishA fully integrated GMP service network operates seamlessly across both China and Europe, combining deep local insight with international regulatory expertise.
In China, the platform supports pharmaceutical companies nationwide in strengthening compliance frameworks, optimizing quality systems, and preparing for global market entry.
In Europe, the network provides locally attuned, regionally aligned regulatory and compliance solutions, ensuring smooth navigation of EU requirements for businesses expanding internationally.
This cross-regional capability ensures consistent, high-quality service delivery, bridging diverse regulatory environments while maintaining alignment with global standards.
MQMR’s GMP service network spans multiple provinces and municipalities across China, with deep expertise in supporting manufacturers of prescription pharmaceuticals, over-the-counter medicines, biologics, vaccines, and advanced therapeutics. Projects range from optimizing quality management systems to facilitating regulatory readiness for both domestic distribution and global export.
Internationally, MQMR operates from its European hub in Italy, delivering compliance and regulatory solutions across the continent. The company works extensively with innovators in small-molecule drugs, biopharmaceuticals, biosimilars, cell and gene therapies, and complex generics—providing market-specific guidance, EU regulatory alignment, and localized compliance strategies for successful market entry.
InnoPharma has successfully passed its annual ISO certification audit. Its CRO service capabilities span Europe, North America, South America, and Australia, enabling efficient global clinical development and market access support for pharmaceutical companies in China.
Its strategic collaboration network has successfully managed and conducted more than 400 clinical trials across Europe, the United States, and the Middle East, involving over 90,000 participants and more than 8,000 clinical trial sites. The organization has extensive experience in large-scale, multinational clinical studies.
In terms of therapeutic areas, its portfolio is broad, with oncology (16%) and rare diseases (11%) as key focus areas. Regarding clinical phases, its projects are primarily Phase III (53%) and Phase II (26%) studies, allowing it to provide comprehensive support for Chinese companies from late-stage clinical development through to international market entry and implementation.
Pellentesque blandit nibh eget egestas molestie justo diam hendrerit tortor et sollicitudin dolor diam vitae orci seieed et ultrices elit. Aliquam arcu purus lacinia sed diam quis ullamcorper venenatis sem.
Italy: Via A. Manzoni 13, 22070 Carbonate (CO), Italy
China — Jiangsu: Wuxi City, Jiangsu Province
China — Zhejiang: Jinhua, Zhejiang Province
Email: helen@itamqmr.com
MQMR SOLUTIONS Srl. | All rights reserved.
